1
|
Lepareur N, Ramée B, Mougin-Degraef M, Bourgeois M. Clinical Advances and Perspectives in Targeted Radionuclide Therapy. Pharmaceutics 2023; 15:1733. [PMID: 37376181 DOI: 10.3390/pharmaceutics15061733] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2023] [Revised: 06/09/2023] [Accepted: 06/13/2023] [Indexed: 06/29/2023] Open
Abstract
Targeted radionuclide therapy has become increasingly prominent as a nuclear medicine subspecialty. For many decades, treatment with radionuclides has been mainly restricted to the use of iodine-131 in thyroid disorders. Currently, radiopharmaceuticals, consisting of a radionuclide coupled to a vector that binds to a desired biological target with high specificity, are being developed. The objective is to be as selective as possible at the tumor level, while limiting the dose received at the healthy tissue level. In recent years, a better understanding of molecular mechanisms of cancer, as well as the appearance of innovative targeting agents (antibodies, peptides, and small molecules) and the availability of new radioisotopes, have enabled considerable advances in the field of vectorized internal radiotherapy with a better therapeutic efficacy, radiation safety and personalized treatments. For instance, targeting the tumor microenvironment, instead of the cancer cells, now appears particularly attractive. Several radiopharmaceuticals for therapeutic targeting have shown clinical value in several types of tumors and have been or will soon be approved and authorized for clinical use. Following their clinical and commercial success, research in that domain is particularly growing, with the clinical pipeline appearing as a promising target. This review aims to provide an overview of current research on targeting radionuclide therapy.
Collapse
Affiliation(s)
- Nicolas Lepareur
- Comprehensive Cancer Center Eugène Marquis, 35000 Rennes, France
- Inserm, INRAE, Institut NUMECAN (Nutrition, Métabolismes et Cancer)-UMR 1317, Univ Rennes, 35000 Rennes, France
| | - Barthélémy Ramée
- Nuclear Medicine Department, Nantes University Hospital, 44000 Nantes, France
| | - Marie Mougin-Degraef
- Nuclear Medicine Department, Nantes University Hospital, 44000 Nantes, France
- Inserm, CNRS, CRCI2NA (Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes-Angers)-UMR 1307, Université de Nantes, ERL 6001, 44000 Nantes, France
| | - Mickaël Bourgeois
- Nuclear Medicine Department, Nantes University Hospital, 44000 Nantes, France
- Inserm, CNRS, CRCI2NA (Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes-Angers)-UMR 1307, Université de Nantes, ERL 6001, 44000 Nantes, France
- Groupement d'Intérêt Public ARRONAX, 1 Rue Aronnax, 44817 Saint Herblain, France
| |
Collapse
|
2
|
Shi H, Cheng Z. MC1R and melanin-based molecular probes for theranostic of melanoma and beyond. Acta Pharmacol Sin 2022; 43:3034-3044. [PMID: 36008707 PMCID: PMC9712491 DOI: 10.1038/s41401-022-00970-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2022] [Accepted: 07/27/2022] [Indexed: 12/12/2022] Open
Abstract
Malignant melanoma is accounting for most of skin cancer-associated mortality. The incidence of melanoma increased every year worldwide especially in western countries. Treatment efficiency is highly related to the stage of melanoma. Therefore, accurate staging and restaging play a pivotal role in the management of melanoma patients. Though 18F-fluorodeoxyglucose (18F-FDG) positron-emission tomography (PET) has been widely used in imaging of tumor metastases, novel radioactive probes for specific targeted imaging of both primary and metastasized melanoma are still desired. Melanocortin receptor 1 (MC1R) and melanin are two promising biomarkers specifically for melanoma, and numerous research groups including us have been actively developing a plethora of radioactive probes based on targeting of MC1R or melanin for over two decades. In this review, some of the MC1R-targeted tracers and melanin-associated molecular imaging probes developed in our research and others have been briefly summarized, and it provides a quick glance of melanoma-targeted probe design and may contribute to further developing novel molecular probes for cancer theranostics.
Collapse
Affiliation(s)
- Hui Shi
- State Key Laboratory of Drug Research, Molecular Imaging Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China
| | - Zhen Cheng
- State Key Laboratory of Drug Research, Molecular Imaging Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
- University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing, 100049, China.
- Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, 264117, China.
| |
Collapse
|
3
|
Bellavia MC, Nyiranshuti L, Latoche JD, Ho KV, Fecek RJ, Taylor JL, Day KE, Nigam S, Pun M, Gallazzi F, Edinger RS, Storkus WJ, Patel RB, Anderson CJ. PET Imaging of VLA-4 in a New BRAF V600E Mouse Model of Melanoma. Mol Imaging Biol 2022; 24:425-433. [PMID: 34694528 PMCID: PMC9183947 DOI: 10.1007/s11307-021-01666-1] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2021] [Revised: 09/28/2021] [Accepted: 10/05/2021] [Indexed: 01/05/2023]
Abstract
PURPOSE Despite unprecedented responses to immune checkpoint inhibitors and targeted therapy in melanoma, a major subset of patients progresses and have few effective salvage options. We have previously demonstrated robust, selective uptake of the peptidomimetic LLP2A labeled with Cu-64 ([64Cu]-LLP2A) for positron emission tomography (PET) imaging in subcutaneous and metastatic models of B16F10 murine melanoma. LLP2A binds with high affinity to very late antigen-4 (VLA-4, integrin α4β1), a transmembrane protein overexpressed in melanoma and other cancers that facilitates tumor growth and metastasis. Yet B16F10 fails to faithfully reflect human melanoma biology, as it lacks certain oncogenic driver mutations, including BRAF mutations found in ≥ 50 % of clinical specimens. Here, we evaluated the PET tracer [64Cu]-CB-TE1A1P-PEG4-LLP2A ([64Cu]-LLP2A) in novel, translational BRAFV600E mutant melanoma models differing in VLA-4 expression-BPR (VLA-4-) and BPRα (VLA-4+). PROCEDURES BPR cells were transduced with α4 (CD49d) to overexpress intact cell surface VLA-4 (BPRα). The binding affinity of [64Cu]-LLP2A to BPR and BPRα cells was determined by saturation binding assays. [64Cu]-LLP2A internalization into B16F10, BPR, and BPRα cells was quantified via a plate-based assay. Tracer biodistribution and PET/CT imaging were evaluated in mice bearing subcutaneous BPR and BPRα tumors. RESULTS [64Cu]-LLP2A demonstrated high binding affinity to BPRα (Kd = 1.4 nM) but indeterminate binding to BPR cells. VLA-4+ BPRα and B16F10 displayed comparable time-dependent [64Cu]-LLP2A internalization, whereas BPR internalization was undetectable. PET/CT showed increased tracer uptake in BPRα tumors vs. BPR tumors in vivo, which was validated by significantly greater (p < 0.0001) BPRα tumor uptake in biodistribution analyses. CONCLUSIONS [64Cu]-LLP2A discriminates BPRα (VLA-4+) vs. BPR (VLA-4-) melanomas in vivo, supporting translation of these BRAF-mutated melanoma models via prospective imaging and theranostic studies. These results extend the utility of LLP2A to selectively target clinically relevant and therapy-resistant tumor variants toward its use for therapeutic patient care.
Collapse
Affiliation(s)
- Michael C Bellavia
- Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA, 15213, USA
| | - Lea Nyiranshuti
- Department of Medicine, University of Pittsburgh, Pittsburgh, PA, 15213, USA
- Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA, 90095, USA
- RayzeBio Inc., San Diego, CA, 92121, USA
| | - Joseph D Latoche
- Department of Medicine, University of Pittsburgh, Pittsburgh, PA, 15213, USA
| | - Khanh-Van Ho
- Department of Chemistry, University of Missouri, Columbia, MO, 65211, USA
| | - Ronald J Fecek
- Department of Dermatology, University of Pittsburgh, Pittsburgh, PA, 15213, USA
- Department of Microbiology and Immunology, Lake Erie College of Osteopathic Medicine at Seton Hill, Greensburg, PA, 15601, USA
| | - Jennifer L Taylor
- Department of Dermatology, University of Pittsburgh, Pittsburgh, PA, 15213, USA
| | - Kathryn E Day
- Department of Medicine, University of Pittsburgh, Pittsburgh, PA, 15213, USA
| | - Shubhanchi Nigam
- Department of Radiology, University of Pittsburgh, Pittsburgh, PA, 15213, USA
- Eurofins Scientific, Philadelphia, PA, 19355, USA
| | - Michael Pun
- Department of Chemistry, University of Missouri, Columbia, MO, 65211, USA
| | - Fabio Gallazzi
- Department of Chemistry, University of Missouri, Columbia, MO, 65211, USA
| | - Robert S Edinger
- Department of Medicine, University of Pittsburgh, Pittsburgh, PA, 15213, USA
- Department of Radiation Oncology, University of Pittsburgh, Pittsburgh, PA, 15213, USA
| | - Walter J Storkus
- Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA, 15213, USA
- Department of Dermatology, University of Pittsburgh, Pittsburgh, PA, 15213, USA
| | - Ravi B Patel
- Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA, 15213, USA.
- Department of Radiation Oncology, University of Pittsburgh, Pittsburgh, PA, 15213, USA.
| | - Carolyn J Anderson
- Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA, 15213, USA.
- Department of Medicine, University of Pittsburgh, Pittsburgh, PA, 15213, USA.
- Department of Chemistry, University of Missouri, Columbia, MO, 65211, USA.
- Department of Radiology, University of Pittsburgh, Pittsburgh, PA, 15213, USA.
- Department of Radiology, University of Missouri, Columbia, MO, 65211, USA.
| |
Collapse
|
4
|
Thivat E, Rouanet J, Auzeloux P, Sas N, Jouberton E, Levesque S, Billoux T, Mansard S, Molnar I, Chanchou M, Fois G, Maigne L, Chezal JM, Miot-Noirault E, D’Incan M, Durando X, Cachin F. Phase I study of [131I] ICF01012, a targeted radionuclide therapy, in metastatic melanoma: MELRIV-1 protocol. BMC Cancer 2022; 22:417. [PMID: 35428211 PMCID: PMC9013026 DOI: 10.1186/s12885-022-09495-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2022] [Accepted: 04/06/2022] [Indexed: 11/12/2022] Open
Abstract
Background Benzamide-based radioligands targeting melanin were first developed for imaging melanoma and then for therapeutic purpose with targeted radionuclide therapy (TRT). [131I]ICF01012 presents a highly favorable pharmacokinetics profile in vivo for therapy. Tumour growth reduction and increase survival have been established in preclinical models of melanoma. According the these preclinical results, we initiate a first-in-human study aimed to determine the recommended dose of [131I]ICF01012 to administer for the treatment of patients with pigmented metastatic melanoma. Methods The MELRIV-1 trial is an open-label, multicentric, dose-escalation phase I trial. The study is divided in 2 steps, a selection part with an IV injection of low activity of [131I]ICF01012 (185 MBq at D0) to select patients who might benefit from [131I]ICF01012 TRT in therapeutic part, i.e. patient presenting at least one tumour lesion with [131I]ICF01012 uptake and an acceptable personalized dosimetry to critical organs (liver, kidney, lung and retina). According to dose escalation scheme driven by a Continual Reassessment Method (CRM) design, a single therapeutic injection of 800 MBq/m2, or 1600 MBq/m2, or 2700 MBq/m2 or 4000 MBq/m2 of [131I]ICF01012 will be administered at D11 (± 4 days). The primary endpoint is the recommended therapeutic dose of [131I]ICF01012, with DLT defined as any grade 3-4 NCI-CT toxicity during the 6 weeks following therapeutic dose. Safety, pharmacokinetic, biodistribution (using planar whole body and SPECT-CT acquisitions), sensitivity / specificity of [131I]ICF01012, and therapeutic efficacy will be assessed as secondary objectives. Patients who received therapeutic injection will be followed until 3 months after TRT. Since 6 to 18 patients are needed for the therapeutic part, up to 36 patients will be enrolled in the selection part. Discussion This study is a first-in-human trial evaluating the [131I]ICF01012 TRT in metastatic malignant melanomas with a diagnostic dose of the [131I]ICF01012 to select the patients who may benefit from a therapeutic dose of [131I]ICF01012, with at least one tumor lesion with [131I]ICF01012 uptake and an acceptable AD to healthy organ. Trial registration Clinicaltrials.gov: NCT03784625. Registered on December 24, 2018. Identifier in French National Agency for the Safety of Medicines and Health Products (ANSM): N°EudraCT 2016-002444-17.
Collapse
|
5
|
Targeting GPCRs and Their Signaling as a Therapeutic Option in Melanoma. Cancers (Basel) 2022; 14:cancers14030706. [PMID: 35158973 PMCID: PMC8833576 DOI: 10.3390/cancers14030706] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2022] [Revised: 01/27/2022] [Accepted: 01/27/2022] [Indexed: 12/10/2022] Open
Abstract
Simple Summary Sixteen G-protein-coupled receptors (GPCRs) have been involved in melanogenesis or melanomagenesis. Here, we review these GPCRs, their associated signaling, and therapies. Abstract G-protein-coupled receptors (GPCRs) serve prominent roles in melanocyte lineage physiology, with an impact at all stages of development, as well as on mature melanocyte functions. GPCR ligands are present in the skin and regulate melanocyte homeostasis, including pigmentation. The role of GPCRs in the regulation of pigmentation and, consequently, protection against external aggression, such as ultraviolet radiation, has long been established. However, evidence of new functions of GPCRs directly in melanomagenesis has been highlighted in recent years. GPCRs are coupled, through their intracellular domains, to heterotrimeric G-proteins, which induce cellular signaling through various pathways. Such signaling modulates numerous essential cellular processes that occur during melanomagenesis, including proliferation and migration. GPCR-associated signaling in melanoma can be activated by the binding of paracrine factors to their receptors or directly by activating mutations. In this review, we present melanoma-associated alterations of GPCRs and their downstream signaling and discuss the various preclinical models used to evaluate new therapeutic approaches against GPCR activity in melanoma. Recent striking advances in our understanding of the structure, function, and regulation of GPCRs will undoubtedly broaden melanoma treatment options in the future.
Collapse
|
6
|
Alipour R, Iravani A, Hicks RJ. PET Imaging of Melanoma. Nucl Med Mol Imaging 2022. [DOI: 10.1016/b978-0-12-822960-6.00123-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
7
|
Akil H, Quintana M, Raymond JH, Billoux T, Benboubker V, Besse S, Auzeloux P, Delmas V, Petit V, Larue L, D’Incan M, Degoul F, Rouanet J. Efficacy of Targeted Radionuclide Therapy Using [ 131I]ICF01012 in 3D Pigmented BRAF- and NRAS-Mutant Melanoma Models and In Vivo NRAS-Mutant Melanoma. Cancers (Basel) 2021; 13:cancers13061421. [PMID: 33804655 PMCID: PMC8003594 DOI: 10.3390/cancers13061421] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2020] [Revised: 03/12/2021] [Accepted: 03/16/2021] [Indexed: 12/13/2022] Open
Abstract
Simple Summary Targeted radionuclide therapy (TRT) aims to selectively deliver radioactive molecules to tumor cells. For this purpose, we deliver iodine-131 ([131I]) to melanoma cells by using our laboratory-developed melanin specific radiotracer, the ICF01012. Approximately 50% and 20%–30% of human melanomas have activating mutation in BRAF or NRAS genes, respectively. These mutations lead to a constitutive activation of the MAPK/ERK pathway, which is known to be involved in tumor cells’ radioresistance. In this work, we showed using 3D in vitro tumor models, an additive efficiency of combining [131I]ICF01012-TRT and MAPK/ERK inhibitors in BRAF- and NRAS-mutant melanoma cells. In mice bearing NRASQ61K-mutated melanoma, TRT induced an impressive decrease in tumor growth, as well as a highly extended survival. Additionally, we showed that TRT reduces the metastatic capacity of melanoma, especially through lymph-node dissemination. These results are therefore of great interest, especially for patients with NRAS-mutant metastatic melanoma who currently lack specific efficient therapies. Abstract Purpose: To assess the efficiency of targeted radionuclide therapy (TRT), alone or in combination with MEK inhibitors (MEKi), in melanomas harboring constitutive MAPK/ERK activation responsible for tumor radioresistance. Methods: For TRT, we used a melanin radiotracer ([131I]ICF01012) currently in phase 1 clinical trial (NCT03784625). TRT alone or combined with MEKi was evaluated in three-dimensional melanoma spheroid models of human BRAFV600E SK-MEL-3, murine NRASQ61K 1007, and WT B16F10 melanomas. TRT in vivo biodistribution, dosimetry, efficiency, and molecular mechanisms were studied using the C57BL/6J-NRASQ61K 1007 syngeneic model. Results: TRT cooperated with MEKi to increase apoptosis in both BRAF- and NRAS-mutant spheroids. NRASQ61K spheroids were highly radiosensitive towards [131I]ICF01012-TRT. In mice bearing NRASQ61K 1007 melanoma, [131I]ICF01012 induced a significant extended survival (92 vs. 44 days, p < 0.0001), associated with a 93-Gy tumor deposit, and reduced lymph-node metastases. Comparative transcriptomic analyses confirmed a decrease in mitosis, proliferation, and metastasis signatures in TRT-treated vs. control tumors and suggest that TRT acts through an increase in oxidation and inflammation and P53 activation. Conclusion: Our data suggest that [131I]ICF01012-TRT and MEKi combination could be of benefit for advanced pigmented BRAF-mutant melanoma care and that [131I]ICF01012 alone could constitute a new potential NRAS-mutant melanoma treatment.
Collapse
Affiliation(s)
- Hussein Akil
- INSERM U1240, University of Clermont Auvergne, 58 rue Montalembert, 63000 Clermont-Ferrand, France; (H.A.); (M.Q.); (V.B.); (S.B.); (P.A.); (M.D.); (F.D.)
- CNRS 7276, INSERM U1262, 2 rue du Pr Descottes, 87025 Limoges, France
| | - Mercedes Quintana
- INSERM U1240, University of Clermont Auvergne, 58 rue Montalembert, 63000 Clermont-Ferrand, France; (H.A.); (M.Q.); (V.B.); (S.B.); (P.A.); (M.D.); (F.D.)
| | - Jérémy H. Raymond
- INSERM U1021, Normal and Pathological Development of Melanocytes, Institut Curie, PSL Research University, Campus Universitaire, 91898 Orsay, France; (J.H.R.); (V.D.); (V.P.); (L.L.)
- Campus Universitaire, University Paris-Sud, University Paris-Saclay, CNRS UMR3347, 91898 Orsay, France
- Equipes Labellisées-Ligue Contre le Cancer, Campus Universitaire, 91898 Orsay, France
| | - Tommy Billoux
- Cirmen, Centre Jean Perrin, 58 rue Montalembert, 63000 Clermont-Ferrand, France;
| | - Valentin Benboubker
- INSERM U1240, University of Clermont Auvergne, 58 rue Montalembert, 63000 Clermont-Ferrand, France; (H.A.); (M.Q.); (V.B.); (S.B.); (P.A.); (M.D.); (F.D.)
| | - Sophie Besse
- INSERM U1240, University of Clermont Auvergne, 58 rue Montalembert, 63000 Clermont-Ferrand, France; (H.A.); (M.Q.); (V.B.); (S.B.); (P.A.); (M.D.); (F.D.)
| | - Philippe Auzeloux
- INSERM U1240, University of Clermont Auvergne, 58 rue Montalembert, 63000 Clermont-Ferrand, France; (H.A.); (M.Q.); (V.B.); (S.B.); (P.A.); (M.D.); (F.D.)
| | - Véronique Delmas
- INSERM U1021, Normal and Pathological Development of Melanocytes, Institut Curie, PSL Research University, Campus Universitaire, 91898 Orsay, France; (J.H.R.); (V.D.); (V.P.); (L.L.)
- Campus Universitaire, University Paris-Sud, University Paris-Saclay, CNRS UMR3347, 91898 Orsay, France
- Equipes Labellisées-Ligue Contre le Cancer, Campus Universitaire, 91898 Orsay, France
| | - Valérie Petit
- INSERM U1021, Normal and Pathological Development of Melanocytes, Institut Curie, PSL Research University, Campus Universitaire, 91898 Orsay, France; (J.H.R.); (V.D.); (V.P.); (L.L.)
- Campus Universitaire, University Paris-Sud, University Paris-Saclay, CNRS UMR3347, 91898 Orsay, France
- Equipes Labellisées-Ligue Contre le Cancer, Campus Universitaire, 91898 Orsay, France
| | - Lionel Larue
- INSERM U1021, Normal and Pathological Development of Melanocytes, Institut Curie, PSL Research University, Campus Universitaire, 91898 Orsay, France; (J.H.R.); (V.D.); (V.P.); (L.L.)
- Campus Universitaire, University Paris-Sud, University Paris-Saclay, CNRS UMR3347, 91898 Orsay, France
- Equipes Labellisées-Ligue Contre le Cancer, Campus Universitaire, 91898 Orsay, France
| | - Michel D’Incan
- INSERM U1240, University of Clermont Auvergne, 58 rue Montalembert, 63000 Clermont-Ferrand, France; (H.A.); (M.Q.); (V.B.); (S.B.); (P.A.); (M.D.); (F.D.)
- Department of Dermatology and Oncodermatology, CHU Estaing, 1 Place Aubrac, 63000 Clermont-Ferrand, France
| | - Françoise Degoul
- INSERM U1240, University of Clermont Auvergne, 58 rue Montalembert, 63000 Clermont-Ferrand, France; (H.A.); (M.Q.); (V.B.); (S.B.); (P.A.); (M.D.); (F.D.)
- CNRS 6293 INSERM U1103, University of Clermont Auvergne, 28, Place Henri Dunant, 63000 Clermont-Ferrand, France
| | - Jacques Rouanet
- INSERM U1240, University of Clermont Auvergne, 58 rue Montalembert, 63000 Clermont-Ferrand, France; (H.A.); (M.Q.); (V.B.); (S.B.); (P.A.); (M.D.); (F.D.)
- Department of Dermatology and Oncodermatology, CHU Estaing, 1 Place Aubrac, 63000 Clermont-Ferrand, France
- Correspondence:
| |
Collapse
|
8
|
Rouanet J, Quintana M, Auzeloux P, Cachin F, Degoul F. Benzamide derivative radiotracers targeting melanin for melanoma imaging and therapy: Preclinical/clinical development and combination with other treatments. Pharmacol Ther 2021; 224:107829. [PMID: 33662452 DOI: 10.1016/j.pharmthera.2021.107829] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/22/2021] [Indexed: 12/16/2022]
Abstract
Cutaneous melanoma arises from proliferating melanocytes, cells specialized in the production of melanin. This property means melanin can be considered as a target for monitoring melanoma patients using nuclear imaging or targeted radionuclide therapy (TRT). Since the 1970s, many researchers have shown that specific molecules can interfere with melanin. This paper reviews some such molecules: benzamide structures improved to increase their pharmacokinetics for imaging or TRT. We first describe the characteristics and biosynthesis of melanin, and the main features of melanin tracers. The second part summarizes the preclinical and corresponding clinical studies on imaging. The last section presents TRT results from ongoing protocols and discusses combinations with other therapies as an opportunity for melanoma non-responders or patients resistant to treatments.
Collapse
Affiliation(s)
- Jacques Rouanet
- Université Clermont Auvergne, INSERM, Imagerie Moléculaire et Stratégies Théranostiques, UMR1240, 58 Rue Montalembert, 63005 Clermont-Ferrand, Cedex, France; Department of Dermatology and Oncodermatology, CHU Estaing, 1 place Lucie et Raymond Aubrac, 63000 Clermont-Ferrand, France; Centre Jean Perrin, Clermont-Ferrand F-63011, France.
| | - Mercedes Quintana
- Université Clermont Auvergne, INSERM, Imagerie Moléculaire et Stratégies Théranostiques, UMR1240, 58 Rue Montalembert, 63005 Clermont-Ferrand, Cedex, France.
| | - Philippe Auzeloux
- Université Clermont Auvergne, INSERM, Imagerie Moléculaire et Stratégies Théranostiques, UMR1240, 58 Rue Montalembert, 63005 Clermont-Ferrand, Cedex, France.
| | - Florent Cachin
- Université Clermont Auvergne, INSERM, Imagerie Moléculaire et Stratégies Théranostiques, UMR1240, 58 Rue Montalembert, 63005 Clermont-Ferrand, Cedex, France; Centre Jean Perrin, Clermont-Ferrand F-63011, France.
| | - Françoise Degoul
- Université Clermont Auvergne, INSERM, Imagerie Moléculaire et Stratégies Théranostiques, UMR1240, 58 Rue Montalembert, 63005 Clermont-Ferrand, Cedex, France.
| |
Collapse
|
9
|
Alpha Radiation as a Way to Target Heterochromatic and Gamma Radiation-Exposed Breast Cancer Cells. Cells 2020; 9:cells9051165. [PMID: 32397212 PMCID: PMC7291130 DOI: 10.3390/cells9051165] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2020] [Revised: 04/19/2020] [Accepted: 05/06/2020] [Indexed: 12/21/2022] Open
Abstract
Compact chromatin is linked to a poor tumour prognosis and resistance to radiotherapy from photons. We investigated DNA damage induction and repair in the context of chromatin structure for densely ionising alpha radiation as well as its therapeutic potential. Chromatin opening by histone deacetylase inhibitor trichostatin A (TSA) pretreatment reduced clonogenic survival and increased γH2AX foci in MDA-MB-231 cells, indicative of increased damage induction by free radicals using gamma radiation. In contrast, TSA pretreatment tended to improve survival after alpha radiation while γH2AX foci were similar or lower; therefore, an increased DNA repair is suggested due to increased access of repair proteins. MDA-MB-231 cells exposed to fractionated gamma radiation (2 Gy × 6) expressed high levels of stem cell markers, elevated heterochromatin H3K9me3 marker, and a trend towards reduced clonogenic survival in response to alpha radiation. There was a higher level of H3K9me3 at baseline, and the ratio of DNA damage induced by alpha vs. gamma radiation was higher in the aggressive MDA-MB-231 cells compared to hormone receptor-positive MCF7 cells. We demonstrate that heterochromatin structure and stemness properties are induced by fractionated radiation exposure. Gamma radiation-exposed cells may be targeted using alpha radiation, and we provide a mechanistic basis for the involvement of chromatin in these effects.
Collapse
|
10
|
Zhang X, Chen F, Turker MZ, Ma K, Zanzonico P, Gallazzi F, Shah MA, Prater AR, Wiesner U, Bradbury MS, McDevitt MR, Quinn TP. Targeted melanoma radiotherapy using ultrasmall 177Lu-labeled α-melanocyte stimulating hormone-functionalized core-shell silica nanoparticles. Biomaterials 2020; 241:119858. [PMID: 32120314 DOI: 10.1016/j.biomaterials.2020.119858] [Citation(s) in RCA: 27] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2019] [Revised: 01/27/2020] [Accepted: 02/10/2020] [Indexed: 02/07/2023]
Abstract
Lutetium-177 (177Lu) radiolabeled ultrasmall (~6 nm dia.) fluorescent core-shell silica nanoparticles (Cornell prime dots or C' dots) were developed for improving efficacy of targeted radiotherapy in melanoma models. PEGylated C' dots were surface engineered to display 10-15 alpha melanocyte stimulating hormone (αMSH) cyclic peptide analogs for targeting the melanocortin-1 receptor (MC1-R) over-expressed on melanoma tumor cells. The 177Lu-DOTA-αMSH-PEG-C' dot product was radiochemically stable, biologically active, and exhibited high affinity cellular binding properties and internalization. Selective tumor uptake and favorable biodistribution properties were also demonstrated, in addition to bulk renal clearance, in syngeneic B16F10 and human M21 xenografted models. Prolonged survival was observed in the treated cohorts relative to controls. Dosimetric analysis showed no excessively high absorbed dose among normal organs. Correlative histopathology of ex vivo treated tumor specimens revealed expected necrotic changes; no acute pathologic findings were noted in the liver or kidneys. Collectively, these results demonstrated that 177Lu-DOTA-αMSH-PEG-C' dot targeted melanoma therapy overcame the unfavorable biological properties and dose-limiting toxicities associated with existing mono-molecular treatments. The unique and tunable surface chemistries of this targeted ultrasmall radiotherapeutic, coupled with its favorable pharmacokinetic properties, substantially improved treatment efficacy and demonstrated a clear survival benefit in melanoma models, which supports its further clinical translation.
Collapse
Affiliation(s)
- Xiuli Zhang
- Harry S. Truman Veterans' Hospital, 800 Hospital Dr., Columbia, MO 65201, United States; Department of Biochemistry, University of Missouri, Columbia, MO 65211, United States
| | - Feng Chen
- Department of Radiology, Sloan Kettering Institute for Cancer Research, New York, NY 10065, United States
| | - Melik Z Turker
- Department of Materials Science and Engineering, Cornell University, Ithaca, NY 14853, United States
| | - Kai Ma
- Elucida Oncology, New York, NY 10016, United States
| | - Pat Zanzonico
- Department of Medical Physics, Sloan Kettering Institute for Cancer Research, New York, NY 10065, United States
| | - Fabio Gallazzi
- Department of Chemistry and Research Core Facilities, University of Missouri, Columbia, MO 65211, United States
| | - Manankumar A Shah
- Harry S. Truman Veterans' Hospital, 800 Hospital Dr., Columbia, MO 65201, United States; Department of Biochemistry, University of Missouri, Columbia, MO 65211, United States
| | - Austin R Prater
- Harry S. Truman Veterans' Hospital, 800 Hospital Dr., Columbia, MO 65201, United States; Department of Biochemistry, University of Missouri, Columbia, MO 65211, United States
| | - Ulrich Wiesner
- Department of Materials Science and Engineering, Cornell University, Ithaca, NY 14853, United States
| | - Michelle S Bradbury
- Department of Radiology, Sloan Kettering Institute for Cancer Research, New York, NY 10065, United States; Molecular Pharmacology Program, Sloan Kettering Institute for Cancer Research, New York, NY 10065, United States
| | - Michael R McDevitt
- Department of Radiology, Sloan Kettering Institute for Cancer Research, New York, NY 10065, United States
| | - Thomas P Quinn
- Harry S. Truman Veterans' Hospital, 800 Hospital Dr., Columbia, MO 65201, United States; Department of Biochemistry, University of Missouri, Columbia, MO 65211, United States.
| |
Collapse
|
11
|
Li M, Sagastume EE, Lee D, McAlister D, DeGraffenreid AJ, Olewine KR, Graves S, Copping R, Mirzadeh S, Zimmerman BE, Larsen R, Johnson FL, Schultz MK. 203/212Pb Theranostic Radiopharmaceuticals for Image-guided Radionuclide Therapy for Cancer. Curr Med Chem 2020; 27:7003-7031. [PMID: 32720598 PMCID: PMC10613023 DOI: 10.2174/0929867327999200727190423] [Citation(s) in RCA: 23] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2020] [Revised: 03/25/2020] [Accepted: 04/15/2020] [Indexed: 02/07/2023]
Abstract
Receptor-targeted image-guided Radionuclide Therapy (TRT) is increasingly recognized as a promising approach to cancer treatment. In particular, the potential for clinical translation of receptor-targeted alpha-particle therapy is receiving considerable attention as an approach that can improve outcomes for cancer patients. Higher Linear-energy Transfer (LET) of alpha-particles (compared to beta particles) for this purpose results in an increased incidence of double-strand DNA breaks and improved-localized cancer-cell damage. Recent clinical studies provide compelling evidence that alpha-TRT has the potential to deliver a significantly more potent anti-cancer effect compared with beta-TRT. Generator-produced 212Pb (which decays to alpha emitters 212Bi and 212Po) is a particularly promising radionuclide for receptor-targeted alpha-particle therapy. A second attractive feature that distinguishes 212Pb alpha-TRT from other available radionuclides is the possibility to employ elementallymatched isotope 203Pb as an imaging surrogate in place of the therapeutic radionuclide. As direct non-invasive measurement of alpha-particle emissions cannot be conducted using current medical scanner technology, the imaging surrogate allows for a pharmacologically-inactive determination of the pharmacokinetics and biodistribution of TRT candidate ligands in advance of treatment. Thus, elementally-matched 203Pb labeled radiopharmaceuticals can be used to identify patients who may benefit from 212Pb alpha-TRT and apply appropriate dosimetry and treatment planning in advance of the therapy. In this review, we provide a brief history on the use of these isotopes for cancer therapy; describe the decay and chemical characteristics of 203/212Pb for their use in cancer theranostics and methodologies applied for production and purification of these isotopes for radiopharmaceutical production. In addition, a medical physics and dosimetry perspective is provided that highlights the potential of 212Pb for alpha-TRT and the expected safety for 203Pb surrogate imaging. Recent and current preclinical and clinical studies are presented. The sum of the findings herein and observations presented provide evidence that the 203Pb/212Pb theranostic pair has a promising future for use in radiopharmaceutical theranostic therapies for cancer.
Collapse
Affiliation(s)
- Mengshi Li
- Department of Radiology, The University of Iowa, Iowa City, IA USA
- Viewpoint Molecular Targeting, Inc., Coralville, IA USA
| | | | - Dongyoul Lee
- Interdisciplinary Graduate Program in Human Toxicology, University of Iowa, Iowa City, IA, USA
| | | | | | | | - Stephen Graves
- Department of Radiology, The University of Iowa, Iowa City, IA USA
| | - Roy Copping
- Oak Ridge National Laboratory, The US Department of Energy, Oak Ridge TN USA
| | - Saed Mirzadeh
- Oak Ridge National Laboratory, The US Department of Energy, Oak Ridge TN USA
| | - Brian E. Zimmerman
- The National Institute of Standards and Technology, Gaithersburg, MD, USA
| | | | - Frances L. Johnson
- Viewpoint Molecular Targeting, Inc., Coralville, IA USA
- Department of Internal Medicine, Carver College of Medicine, The University of Iowa, Iowa City, Iowa USA
| | - Michael K. Schultz
- Department of Radiology, The University of Iowa, Iowa City, IA USA
- Viewpoint Molecular Targeting, Inc., Coralville, IA USA
- Interdisciplinary Graduate Program in Human Toxicology, University of Iowa, Iowa City, IA, USA
- Department of Chemistry, The University of Iowa, Iowa City, IA, USA
| |
Collapse
|
12
|
Akil H, Rouanet J, Viallard C, Besse S, Auzeloux P, Chezal JM, Miot-Noirault E, Quintana M, Degoul F. Targeted Radionuclide Therapy Decreases Melanoma Lung Invasion by Modifying Epithelial-Mesenchymal Transition-Like Mechanisms. Transl Oncol 2019; 12:1442-1452. [PMID: 31421458 PMCID: PMC6704444 DOI: 10.1016/j.tranon.2019.07.015] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2019] [Revised: 07/17/2019] [Accepted: 07/18/2019] [Indexed: 12/14/2022] Open
Abstract
Melanin-radiolabeled molecules for targeted radionuclide therapy (TRT) provide a promising approach for the treatment of pigmented melanoma. Among these radiolabeled molecules, the iodinated melanin-specific binding molecule ([131I]ICF01012) has shown a significant antitumor effect on metastatic melanoma preclinical models. We report herein that [131I]ICF01012 decreases the epithelial-mesenshymal transition-like (EMT-like) markers in both in vivo and in vitro three-dimensional (3D) melanoma spheroid models. [131I]ICF01012 spheroids irradiation resulted in reduced clonogenic capacity of all pigmented spheroids accompanied by increased protein expression levels of phosphorylated H2A.X, p53 and its downstream target p21. In addition, [131I]ICF01012 treatment leads to a significant increase of cell pigmentation as demonstrated in SK-MEL3 human xenograft model. We also showed that [131I]ICF01012 decreases the size and the number of melanoma lung colonies in the syngeneic murine B16BL6 in vivo model assessing its potentiality to kill circulating tumor cells. Taken together, these results indicate that [131I]ICF01012 reduces metastatic capacity of melanoma cells presumably through EMT-like reduction and cell differentiation induction.
Collapse
Affiliation(s)
- Hussein Akil
- UMR 1240 INSERM, University of Clermont Auvergne, Clermont-Ferrand, France.
| | - Jacques Rouanet
- UMR 1240 INSERM, University of Clermont Auvergne, Clermont-Ferrand, France; Department of Dermatology and Oncodermatology, CHU Estaing, Clermont-Ferrand, France; Centre Jean Perrin, Clermont-Ferrand, France.
| | - Claire Viallard
- UMR 1240 INSERM, University of Clermont Auvergne, Clermont-Ferrand, France.
| | - Sophie Besse
- UMR 1240 INSERM, University of Clermont Auvergne, Clermont-Ferrand, France.
| | - Philippe Auzeloux
- UMR 1240 INSERM, University of Clermont Auvergne, Clermont-Ferrand, France.
| | - Jean-Michel Chezal
- UMR 1240 INSERM, University of Clermont Auvergne, Clermont-Ferrand, France.
| | | | - Mercedes Quintana
- UMR 1240 INSERM, University of Clermont Auvergne, Clermont-Ferrand, France.
| | - Françoise Degoul
- UMR 1240 INSERM, University of Clermont Auvergne, Clermont-Ferrand, France.
| |
Collapse
|
13
|
Allen KJH, Jiao R, Malo ME, Frank C, Fisher DR, Rickles D, Dadachova E. Comparative Radioimmunotherapy of Experimental Melanoma with Novel Humanized Antibody to Melanin Labeled with 213Bismuth and 177Lutetium. Pharmaceutics 2019; 11:E348. [PMID: 31323785 PMCID: PMC6680821 DOI: 10.3390/pharmaceutics11070348] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2019] [Revised: 07/11/2019] [Accepted: 07/11/2019] [Indexed: 12/19/2022] Open
Abstract
Melanoma is a cancer with increasing incidence and there is a need for alternatives to immunotherapy within effective approaches to treatment of metastatic melanoma. We performed comparative radioimmunotherapy (RIT) of experimental B16-F10 melanoma with novel humanized IgG to melanin h8C3 labeled with a beta emitter, 177Lu, and an alpha-emitter, 213Bi, as well as biodistribution, microSPECT/CT imaging, and mouse and human dosimetry calculations. microSPECT/CT imaging showed that a humanized antibody that targets "free" melanin in the tumor microenvironment had high tumor uptake in B16F10 murine melanoma in C57Bl/6 mice, with little to no uptake in naturally melanized tissues. Extrapolation of the mouse dosimetry data to an adult human demonstrated that doses delivered to major organs and the whole body by 177Lu-h8C3 would be approximately two times higher than those delivered by 213Bi-h8C3, while the doses to the tumor would be almost similar. RIT results indicated that 213Bi-h8C3 was more effective in slowing down the tumor growth than 177Lu-h8C3, while both radiolabeled antibodies did not produce significant hematologic or systemic side effects. We concluded that h8C3 antibody labeled with 213Bi is a promising reagent for translation into a clinical trial in patients with metastatic melanoma.
Collapse
Affiliation(s)
- Kevin J H Allen
- College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada
| | - Rubin Jiao
- College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada
| | - Mackenzie E Malo
- College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada
| | - Connor Frank
- College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada
| | - Darrell R Fisher
- Versant Medical Physics and Radiation Safety, Richland, WA 99354, USA
| | | | - Ekaterina Dadachova
- College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada.
| |
Collapse
|
14
|
Wei W, Jiang D, Ehlerding EB, Barnhart TE, Yang Y, Engle JW, Luo Q, Huang P, Cai W. CD146-Targeted Multimodal Image-Guided Photoimmunotherapy of Melanoma. ADVANCED SCIENCE (WEINHEIM, BADEN-WURTTEMBERG, GERMANY) 2019; 6:1801237. [PMID: 31065511 PMCID: PMC6498137 DOI: 10.1002/advs.201801237] [Citation(s) in RCA: 40] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/31/2018] [Revised: 02/01/2019] [Indexed: 05/23/2023]
Abstract
For melanoma resistant to molecularly targeted therapy and immunotherapy, new treatment strategies are urgently needed. A molecularly targeted theranostic pair may thus be of importance, where the diagnostic probe facilitates patient stratification and the therapeutic companion treats the selected cases. For this purpose, flow cytometry is used to assess the CD146 level in melanoma cells. Based on YY146, a CD146-specific monoclonal antibody, an imaging probe 89Zr-Df-YY146 is synthesized and its diagnostic performance is evaluated by positron emission tomography (PET) imaging. Furthermore, a photoimmunotherapy (PIT) agent IR700-YY146 is developed and the therapeutic effect of IR700-YY146 PIT is assessed comprehensively. CD146 is highly expressed in A375 and SK-MEL-5 cells. 89Zr-Df-YY146 PET readily detects CD146-positive A375 melanomas. Tumor accumulation of 89Zr-Df-YY146 peaks at 72 h with an uptake value of 26.48 ± 3.28%ID g-1, whereas the highest uptake of the nonspecific 89Zr-Df-IgG is 4.80 ± 1.75%ID g-1. More importantly, IR700-YY146 PIT effectively inhibits the growth of A375 tumors, owing to production of reactive oxygen species, decreased glucose metabolism, and reduced expression of CD146. To conclude, 89Zr-Df-YY146 and IR700-YY146 are a promising theranostic pair with the former revealing CD146 expression in melanoma as a PET probe and the latter specifically treating CD146-positive melanoma as an effective PIT agent.
Collapse
Affiliation(s)
- Weijun Wei
- Department of Nuclear MedicineShanghai Jiao Tong University Affiliated Sixth People's Hospital600 Yishan RoadShanghai200233China
- Department of RadiologyUniversity of Wisconsin–MadisonMadisonWI53705USA
| | - Dawei Jiang
- Department of RadiologyUniversity of Wisconsin–MadisonMadisonWI53705USA
- Guangdong Key Laboratory for Biomedical Measurements and Ultrasound ImagingCarson International Cancer CenterLaboratory of Evolutionary TheranosticsSchool of Biomedical EngineeringHealth Science CenterShenzhen UniversityShenzhen518060China
| | - Emily B. Ehlerding
- Department of Medical PhysicsUniversity of Wisconsin–MadisonMadisonWI53705USA
| | - Todd E. Barnhart
- Department of Medical PhysicsUniversity of Wisconsin–MadisonMadisonWI53705USA
| | - Yunan Yang
- Department of RadiologyUniversity of Wisconsin–MadisonMadisonWI53705USA
| | - Jonathan W. Engle
- Department of Medical PhysicsUniversity of Wisconsin–MadisonMadisonWI53705USA
| | - Quan‐Yong Luo
- Department of Nuclear MedicineShanghai Jiao Tong University Affiliated Sixth People's Hospital600 Yishan RoadShanghai200233China
| | - Peng Huang
- Guangdong Key Laboratory for Biomedical Measurements and Ultrasound ImagingCarson International Cancer CenterLaboratory of Evolutionary TheranosticsSchool of Biomedical EngineeringHealth Science CenterShenzhen UniversityShenzhen518060China
| | - Weibo Cai
- Department of RadiologyUniversity of Wisconsin–MadisonMadisonWI53705USA
- Department of Medical PhysicsUniversity of Wisconsin–MadisonMadisonWI53705USA
- University of Wisconsin Carbone Cancer CenterMadisonWI53705USA
| |
Collapse
|
15
|
Targeting the Tetraspanins with Monoclonal Antibodies in Oncology: Focus on Tspan8/Co-029. Cancers (Basel) 2019; 11:cancers11020179. [PMID: 30769765 PMCID: PMC6406856 DOI: 10.3390/cancers11020179] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2018] [Revised: 01/28/2019] [Accepted: 01/30/2019] [Indexed: 12/12/2022] Open
Abstract
Tetraspanins are exposed at the surface of cellular membranes, which allows for the fixation of cognate antibodies. Developing specific antibodies in conjunction with genetic data would largely contribute to deciphering their biological behavior. In this short review, we summarize the main functions of Tspan8/Co-029 and its role in the biology of tumor cells. Based on data collected from recently reported studies, the possibilities of using antibodies to target Tspan8 in immunotherapy or radioimmunotherapy approaches are also discussed.
Collapse
|
16
|
Isoliquiritigenin Induces Mitochondrial Dysfunction and Apoptosis by Inhibiting mitoNEET in a Reactive Oxygen Species-Dependent Manner in A375 Human Melanoma Cells. OXIDATIVE MEDICINE AND CELLULAR LONGEVITY 2019; 2019:9817576. [PMID: 30805086 PMCID: PMC6360568 DOI: 10.1155/2019/9817576] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/05/2018] [Revised: 09/22/2018] [Accepted: 11/04/2018] [Indexed: 11/25/2022]
Abstract
The mitochondrial protein mitoNEET is a type of iron-sulfur protein localized to the outer membrane of mitochondria and is involved in a variety of human pathologies including cystic fibrosis, diabetes, muscle atrophy, and neurodegeneration. In the current study, we found that isoliquiritigenin (ISL), one of the components of the root of Glycyrrhiza glabra L., could decrease the expression of mitoNEET in A375 melanoma cells. We also demonstrated that mitoNEET could regulate the content of reactive oxygen species (ROS), by showing that the ISL-mediated increase in the cellular ROS content could be mitigated by the mitoNEET overexpression. We also confirmed the important role of ROS in ISL-treated A375 cells. The increased apoptosis rate and the decreased mitochondrial membrane potential were mitigated by the overexpression of mitoNEET in A375 cells. These findings indicated that ISL could decrease the expression of mitoNEET, which regulated ROS content and subsequently induced mitochondrial dysfunction and apoptosis in A375 cells. Our findings also highlight mitoNEET as a promising mitochondrial target for cancer therapy.
Collapse
|
17
|
Xu X, Yuan L, Gai Y, Liu Q, Yin L, Jiang Y, Wang Y, Zhang Y, Lan X. Targeted radiotherapy of pigmented melanoma with 131I-5-IPN. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH : CR 2018; 37:306. [PMID: 30537980 PMCID: PMC6288928 DOI: 10.1186/s13046-018-0983-0] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/05/2018] [Accepted: 11/26/2018] [Indexed: 12/25/2022]
Abstract
Purpose There has been no satisfactory treatment for advanced melanoma until now. Targeted radionuclide therapy (TRNT) may be a promising option for this heretofore lethal disease. Our goal in this study was to synthesize 131I-N-(2-(diethylamino)ethyl)-5-(iodo-131I)picolinamide (131I-5-IPN) and evaluate its therapeutic ability and toxicity as a radioiodinated melanin-targeting therapeutic agent. Methods The trimethylstannyl precursor was synthesized and labeled with 131I to obtain 131I-5-IPN. The pharmacokinetics of 131I-5-IPN was evaluated through SPECT imaging, and its biodistribution was assessed in B16F10 tumor models and in A375 human-to-mouse xenografts. For TRNT, B16F10 melanoma-bearing mice were randomly allocated to receive one of five treatments (n = 10 per group): group A (the control group) received 0.1 mL saline; group B was treated with an equimolar dose of unlabeled precursor; group C received 18.5 MBq of [131I]NaI; group D and E received one or two dose of 18.5 MBq 131I-5-IPN, respectively. TRNT efficacy was evaluated through tumor volume measurement and biology study. The toxic effects of 131I-5-IPN on vital organs were assessed with laboratory tests and histopathological examination. The radiation absorbed dose to vital organs was estimated based on biodistribution data. Results 131I-5-IPN was successfully prepared with a good radiochemistry yield (55% ± 5%, n = 5), and it exhibited a high uptake ratio in melanin-positive B16F10 cells which indicating high specificity. SPECT imaging and biodistribution of 131I-5-IPN showed lasting high tumor uptake in pigmented B16F10 models for 72 h. TRNT with 131I-5-IPN led to a significant anti-tumor effect and Groups D and E displayed an extended median survival compared to groups A, B, and C. The highest absorbed dose to a vital organ was 0.25 mSv/MBq to the liver; no obvious injury to the liver or kidneys was observed during treatment. 131I-5-IPN treatment was associated with reduction of expression of proliferating cell nuclear antigen (PCNA) and Ki67 and cell cycle blockage in G2/M phase in tumor tissues. Decreased vascular endothelial growth factor and CD31 expression, implying reduced tumor growth, was noted after TRNT. Conclusion We successfully synthesized 131I-5-IPN, which presents long-time retention in melanotic melanoma. TRNT with 131I-5-IPN has the potential to be a safe and effective strategy for management of pigmented melanoma.
Collapse
Affiliation(s)
- Xiaodong Xu
- Department of Nuclear Medicine, Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Ave, Wuhan, 430022, Hubei Province, China.,Hubei Key Laboratory of Molecular Imaging, Wuhan, 430022, China
| | - Lujie Yuan
- Department of Nuclear Medicine, Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Ave, Wuhan, 430022, Hubei Province, China.,Hubei Key Laboratory of Molecular Imaging, Wuhan, 430022, China
| | - Yongkang Gai
- Department of Nuclear Medicine, Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Ave, Wuhan, 430022, Hubei Province, China.,Hubei Key Laboratory of Molecular Imaging, Wuhan, 430022, China
| | - Qingyao Liu
- Department of Nuclear Medicine, Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Ave, Wuhan, 430022, Hubei Province, China.,Hubei Key Laboratory of Molecular Imaging, Wuhan, 430022, China
| | - Lianglan Yin
- Department of Nuclear Medicine, Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Ave, Wuhan, 430022, Hubei Province, China.,Hubei Key Laboratory of Molecular Imaging, Wuhan, 430022, China
| | - Yaqun Jiang
- Department of Nuclear Medicine, Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Ave, Wuhan, 430022, Hubei Province, China.,Hubei Key Laboratory of Molecular Imaging, Wuhan, 430022, China
| | - Yichun Wang
- Department of Nuclear Medicine, Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Ave, Wuhan, 430022, Hubei Province, China.,Hubei Key Laboratory of Molecular Imaging, Wuhan, 430022, China
| | - Yongxue Zhang
- Department of Nuclear Medicine, Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Ave, Wuhan, 430022, Hubei Province, China.,Hubei Key Laboratory of Molecular Imaging, Wuhan, 430022, China
| | - Xiaoli Lan
- Department of Nuclear Medicine, Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Ave, Wuhan, 430022, Hubei Province, China. .,Hubei Key Laboratory of Molecular Imaging, Wuhan, 430022, China.
| |
Collapse
|
18
|
Mellhammar E, Dahlbom M, Evans-Axelsson S, Strand SE. Preserving Preclinical PET Quality During Intratherapeutic Imaging in Radionuclide Therapy with Rose Metal Shielding Reducing Photon Flux. J Nucl Med 2018; 60:710-715. [PMID: 30389819 DOI: 10.2967/jnumed.118.217117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2018] [Accepted: 10/05/2018] [Indexed: 11/16/2022] Open
Abstract
Performing PET imaging during ongoing radionuclide therapy can be a promising method to follow tumor response in vivo. However, the high therapeutic activity can interfere with the PET camera performance and degrade both image quality and quantitative capabilities. As a solution, low-energy photon emissions from the therapeutic radionuclide can be highly attenuated, still allowing sufficient detection of annihilation photons in coincidence. Methods: Hollow Rose metal cylinders with walls 2-4 mm thick were used to shield a 22Na point source and a uniform phantom filled with 18F as they were imaged on a preclinical PET camera with increasing activities of 177Lu. A mouse with a subcutaneous tumor was injected with 18F-FDG and imaged with an additional 120 MBq of 177Lu and repeated with shields surrounding the animal. Results: The addition of 177Lu to the volume imaged continuously degraded the image quality with increasing activity. The image quality was improved when shielding was introduced. The shields showed a high ability to produce stable and reproducible results for both spatial resolution and quantification of up to 120 MBq of 177Lu activity (maximum activity tested). Conclusion: Without shielding, the activity quantification will be inaccurate for time points at which therapeutic activities are high. The suggested method shows that the shields reduce the noise induced by the 177Lu and therefore enable longitudinal quantitative intratherapeutic imaging studies.
Collapse
Affiliation(s)
- Emma Mellhammar
- Division of Oncology and Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden
| | - Magnus Dahlbom
- Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California; and
| | - Susan Evans-Axelsson
- Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California; and
| | - Sven-Erik Strand
- Division of Oncology and Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden.,Division of Medical Radiation Physics, Department of Clinical Sciences, Lund University, Lund, Sweden
| |
Collapse
|
19
|
Cheng L, Brzozowska B, Sollazzo A, Lundholm L, Lisowska H, Haghdoost S, Wojcik A. Simultaneous induction of dispersed and clustered DNA lesions compromises DNA damage response in human peripheral blood lymphocytes. PLoS One 2018; 13:e0204068. [PMID: 30379881 PMCID: PMC6209146 DOI: 10.1371/journal.pone.0204068] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2018] [Accepted: 08/31/2018] [Indexed: 11/18/2022] Open
Abstract
Due to its ability to induce DNA damage in a space and time controlled manner, ionising radiation is a unique tool for studying the mechanisms of DNA repair. The biological effectiveness of ionising radiation is related to the ionisation density which is defined by the linear energy transfer (LET). Alpha particles are characterised by high LET, while X-rays by low LET values. An interesting question is how cells react when exposed to a mixed beam of high and low LET radiation. In an earlier study carried out with human peripheral blood lymphocytes (PBL) we could demonstrate that alpha radiation X-rays interact in producing more chromosomal aberrations than expected based on additivity. The aim of the present investigation was to look at the mechanism of the interaction, especially with respect to the question if it is due to an augmented level of initial damage or impaired DNA repair. PBL were exposed to various doses of alpha particles, X-rays and mixed beams. DNA damage and the kinetics of damage repair was quantified by the alkaline comet assay. The levels of phosphorylated, key DNA damage response (DDR) proteins ATM, p53 and DNA-PK were measured by Western blotting and mRNA levels of 6 damage-responsive genes were measured by qPCR. Alpha particles and X-rays interact in inducing DNA damage above the level predicted by assuming additivity and that the repair of damage occurs with a delay. The activation levels of DDR proteins and mRNA levels of the studied genes were highest in cells exposed to mixed beams. The results substantiate the idea that exposure to mixed beams presents a challenge for the cellular DDR system.
Collapse
Affiliation(s)
- Lei Cheng
- Centre for Radiation Protection Research, Department of Molecular Biosciences, the Wenner-Gren Institute, Stockholm University, Stockholm, Sweden
| | - Beata Brzozowska
- Centre for Radiation Protection Research, Department of Molecular Biosciences, the Wenner-Gren Institute, Stockholm University, Stockholm, Sweden
- Biomedical Physics Division, Faculty of Physics, University of Warsaw, Warszawa, Poland
| | - Alice Sollazzo
- Centre for Radiation Protection Research, Department of Molecular Biosciences, the Wenner-Gren Institute, Stockholm University, Stockholm, Sweden
| | - Lovisa Lundholm
- Centre for Radiation Protection Research, Department of Molecular Biosciences, the Wenner-Gren Institute, Stockholm University, Stockholm, Sweden
| | - Halina Lisowska
- Institute of Biology, Jan Kochanowski University, Kielce, Poland
| | - Siamak Haghdoost
- Centre for Radiation Protection Research, Department of Molecular Biosciences, the Wenner-Gren Institute, Stockholm University, Stockholm, Sweden
| | - Andrzej Wojcik
- Centre for Radiation Protection Research, Department of Molecular Biosciences, the Wenner-Gren Institute, Stockholm University, Stockholm, Sweden
- Institute of Biology, Jan Kochanowski University, Kielce, Poland
| |
Collapse
|
20
|
Jouberton E, Perrot Y, Dirat B, Billoux T, Auzeloux P, Cachin F, Chezal J, Filaire M, Labarre P, Miot‐Noirault E, Millardet C, Valla C, Vidal A, Degoul F, Maigne L. Radiation dosimetry of [
131
I]ICF01012 in rabbits: Application to targeted radionuclide therapy for human melanoma treatment. Med Phys 2018; 45:5251-5262. [DOI: 10.1002/mp.13165] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2018] [Revised: 07/24/2018] [Accepted: 08/06/2018] [Indexed: 01/28/2023] Open
Affiliation(s)
- Elodie Jouberton
- Centre Jean Perrin Clermont‐Ferrand F‐63011 France
- Université Clermont Auvergne INSERM Imagerie Moléculaire et Stratégies Théranostiques UMR1240 58 Rue Montalembert 63 005 Clermont‐Ferrand CedexFrance
| | - Yann Perrot
- Université Clermont Auvergne CNRS/IN2P3 Laboratoire de Physique de Clermont UMR6533 4 Avenue Blaise Pascal TSA 60026 CS 60026 63178 Aubière Cedex France
| | - Béatrice Dirat
- Université Clermont Auvergne INSERM Imagerie Moléculaire et Stratégies Théranostiques UMR1240 58 Rue Montalembert 63 005 Clermont‐Ferrand CedexFrance
| | | | - Philippe Auzeloux
- Centre Jean Perrin Clermont‐Ferrand F‐63011 France
- Université Clermont Auvergne INSERM Imagerie Moléculaire et Stratégies Théranostiques UMR1240 58 Rue Montalembert 63 005 Clermont‐Ferrand CedexFrance
| | - Florent Cachin
- Centre Jean Perrin Clermont‐Ferrand F‐63011 France
- Université Clermont Auvergne INSERM Imagerie Moléculaire et Stratégies Théranostiques UMR1240 58 Rue Montalembert 63 005 Clermont‐Ferrand CedexFrance
| | - Jean‐Michel Chezal
- Université Clermont Auvergne INSERM Imagerie Moléculaire et Stratégies Théranostiques UMR1240 58 Rue Montalembert 63 005 Clermont‐Ferrand CedexFrance
| | - Marc Filaire
- Centre Jean Perrin Clermont‐Ferrand F‐63011 France
| | - Pierre Labarre
- Université Clermont Auvergne INSERM Imagerie Moléculaire et Stratégies Théranostiques UMR1240 58 Rue Montalembert 63 005 Clermont‐Ferrand CedexFrance
| | - Elisabeth Miot‐Noirault
- Université Clermont Auvergne INSERM Imagerie Moléculaire et Stratégies Théranostiques UMR1240 58 Rue Montalembert 63 005 Clermont‐Ferrand CedexFrance
| | | | - Clémence Valla
- Centre Jean Perrin Clermont‐Ferrand F‐63011 France
- Université Clermont Auvergne INSERM Imagerie Moléculaire et Stratégies Théranostiques UMR1240 58 Rue Montalembert 63 005 Clermont‐Ferrand CedexFrance
| | - Aurélien Vidal
- Université Clermont Auvergne INSERM Imagerie Moléculaire et Stratégies Théranostiques UMR1240 58 Rue Montalembert 63 005 Clermont‐Ferrand CedexFrance
| | - Françoise Degoul
- Université Clermont Auvergne INSERM Imagerie Moléculaire et Stratégies Théranostiques UMR1240 58 Rue Montalembert 63 005 Clermont‐Ferrand CedexFrance
| | - Lydia Maigne
- Université Clermont Auvergne CNRS/IN2P3 Laboratoire de Physique de Clermont UMR6533 4 Avenue Blaise Pascal TSA 60026 CS 60026 63178 Aubière Cedex France
| |
Collapse
|
21
|
Nosanchuk JD, Jeyakumar A, Ray A, Revskaya E, Jiang Z, Bryan RA, Allen KJH, Jiao R, Malo ME, Gómez BL, Morgenstern A, Bruchertseifer F, Rickles D, Thornton GB, Bowen A, Casadevall A, Dadachova E. Structure-function analysis and therapeutic efficacy of antibodies to fungal melanin for melanoma radioimmunotherapy. Sci Rep 2018; 8:5466. [PMID: 29615812 PMCID: PMC5882926 DOI: 10.1038/s41598-018-23889-z] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2017] [Accepted: 03/22/2018] [Indexed: 02/06/2023] Open
Abstract
Metastatic melanoma remains difficult to treat despite recent approvals of several new drugs. Recently we reported encouraging results of Phase I clinical trial of radiolabeled with 188Re murine monoclonal IgM 6D2 to melanin in patients with Stage III/IV melanoma. Subsequently we generated a novel murine IgG 8C3 to melanin. IgGs are more amenable to humanization and cGMP (current Good Manufacturing Practice) manufacturing than IgMs. We performed comparative structural analysis of melanin-binding IgM 6D2 and IgG 8C3. The therapeutic efficacy of 213Bi- and 188Re-labeled 8C3 and its comparison with anti-CTLA4 immunotherapy was performed in B16-F10 murine melanoma model. The primary structures of these antibodies revealed significant homology, with the CDRs containing a high percentage of positively charged amino acids. The 8C3 model has a negatively charged binding surface and significant number of aromatic residues in its H3 domain, suggesting that hydrophobic interactions contribute to the antibody-melanin interaction. Radiolabeled IgG 8C3 showed significant therapeutic efficacy in murine melanoma, safety towards healthy melanin-containing tissues and favorable comparison with the anti-CTLA4 antibody. We have demonstrated that antibody binding to melanin relies on both charge and hydrophobic interactions while the in vivo data supports further development of 8C3 IgG as radioimmunotherapy reagent for metastatic melanoma.
Collapse
Affiliation(s)
- J D Nosanchuk
- Albert Einstein College of Medicine, Bronx, New York, USA
| | - A Jeyakumar
- Albert Einstein College of Medicine, Bronx, New York, USA
| | - A Ray
- Albert Einstein College of Medicine, Bronx, New York, USA
| | - E Revskaya
- Albert Einstein College of Medicine, Bronx, New York, USA
| | - Z Jiang
- Albert Einstein College of Medicine, Bronx, New York, USA
| | - R A Bryan
- Albert Einstein College of Medicine, Bronx, New York, USA
| | - K J H Allen
- University of Saskatchewan, Saskatoon, SK, Canada
| | - R Jiao
- University of Saskatchewan, Saskatoon, SK, Canada
| | - M E Malo
- University of Saskatchewan, Saskatoon, SK, Canada
| | - B L Gómez
- School of Medicine and Health Sciences, Universidad Rosario, Bogota, Colombia
| | - A Morgenstern
- European Commission, Joint Research Centre, Directorate for Nuclear Safety and Security, Karlsruhe, Germany
| | - F Bruchertseifer
- European Commission, Joint Research Centre, Directorate for Nuclear Safety and Security, Karlsruhe, Germany
| | - D Rickles
- RadImmune Therapeutics, Tarrytown, NY, USA
| | | | - A Bowen
- Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
| | - A Casadevall
- Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
| | - E Dadachova
- University of Saskatchewan, Saskatoon, SK, Canada.
| |
Collapse
|
22
|
Progress in Targeted Alpha-Particle Therapy. What We Learned about Recoils Release from In Vivo Generators. Molecules 2018; 23:molecules23030581. [PMID: 29510568 PMCID: PMC6017877 DOI: 10.3390/molecules23030581] [Citation(s) in RCA: 69] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2018] [Revised: 02/26/2018] [Accepted: 02/28/2018] [Indexed: 12/02/2022] Open
Abstract
This review summarizes recent progress and developments as well as the most important pitfalls in targeted alpha-particle therapy, covering single alpha-particle emitters as well as in vivo alpha-particle generators. It discusses the production of radionuclides like 211At, 223Ra, 225Ac/213Bi, labelling and delivery employing various targeting vectors (small molecules, chelators for alpha-emitting nuclides and their biomolecular targets as well as nanocarriers), general radiopharmaceutical issues, preclinical studies, and clinical trials including the possibilities of therapy prognosis and follow-up imaging. Special attention is given to the nuclear recoil effect and its impacts on the possible use of alpha emitters for cancer treatment, proper dose estimation, and labelling chemistry. The most recent and important achievements in the development of alpha emitters carrying vectors for preclinical and clinical use are highlighted along with an outlook for future developments.
Collapse
|
23
|
Wei W, Ehlerding EB, Lan X, Luo Q, Cai W. PET and SPECT imaging of melanoma: the state of the art. Eur J Nucl Med Mol Imaging 2018; 45:132-150. [PMID: 29085965 PMCID: PMC5700861 DOI: 10.1007/s00259-017-3839-5] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2017] [Accepted: 09/18/2017] [Indexed: 12/12/2022]
Abstract
Melanoma represents the most aggressive form of skin cancer, and its incidence continues to rise worldwide. 18F-FDG PET imaging has transformed diagnostic nuclear medicine and has become an essential component in the management of melanoma, but still has its drawbacks. With the rapid growth in the field of nuclear medicine and molecular imaging, a variety of promising probes that enable early diagnosis and detection of melanoma have been developed. The substantial preclinical success of melanin- and peptide-based probes has recently resulted in the translation of several radiotracers to clinical settings for noninvasive imaging and treatment of melanoma in humans. In this review, we focus on the latest developments in radiolabeled molecular imaging probes for melanoma in preclinical and clinical settings, and discuss the challenges and opportunities for future development.
Collapse
Affiliation(s)
- Weijun Wei
- Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, 600# Yishan Road, Shanghai, 200233, China
- Department of Radiology, University of Wisconsin-Madison, Room 7137, 1111 Highland Avenue, Madison, WI, 53705-2275, USA
| | - Emily B Ehlerding
- Department of Medical Physics, University of Wisconsin-Madison, Madison, WI, 53705, USA
| | - Xiaoli Lan
- Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Hubei Key Laboratory of Molecular Imaging, No. 1277 Jiefang Ave, Wuhan, 430022, China.
| | - Quanyong Luo
- Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, 600# Yishan Road, Shanghai, 200233, China.
| | - Weibo Cai
- Department of Radiology, University of Wisconsin-Madison, Room 7137, 1111 Highland Avenue, Madison, WI, 53705-2275, USA.
- Department of Medical Physics, University of Wisconsin-Madison, Madison, WI, 53705, USA.
- University of Wisconsin Carbone Cancer Center, Madison, WI, 53705, USA.
| |
Collapse
|
24
|
Li M, Zhang X, Quinn TP, Lee D, Liu D, Kunkel F, Zimmerman BE, McAlister D, Olewein K, Menda Y, Mirzadeh S, Copping R, Johnson FL, Schultz MK. Automated cassette-based production of high specific activity [ 203/212Pb]peptide-based theranostic radiopharmaceuticals for image-guided radionuclide therapy for cancer. Appl Radiat Isot 2017; 127:52-60. [PMID: 28521118 PMCID: PMC6295910 DOI: 10.1016/j.apradiso.2017.05.006] [Citation(s) in RCA: 30] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2017] [Revised: 04/29/2017] [Accepted: 05/06/2017] [Indexed: 01/28/2023]
Abstract
A method for preparation of Pb-212 and Pb-203 labeled chelator-modified peptide-based radiopharmaceuticals for cancer imaging and radionuclide therapy has been developed and adapted for automated clinical production. Pre-concentration and isolation of radioactive Pb2+ from interfering metals in dilute hydrochloric acid was optimized using a commercially-available Pb-specific chromatography resin packed in disposable plastic columns. The pre-concentrated radioactive Pb2+ is eluted in NaOAc buffer directly to the reaction vessel containing chelator-modified peptides. Radiolabeling was found to proceed efficiently at 85°C (45min; pH 5.5). The specific activity of radiolabeled conjugates was optimized by separation of radiolabeled conjugates from unlabeled peptide via HPLC. Preservation of bioactivity was confirmed by in vivo biodistribution of Pb-203 and Pb-212 labeled peptides in melanoma-tumor-bearing mice. The approach has been found to be robustly adaptable to automation and a cassette-based fluid-handling system (Modular Lab Pharm Tracer) has been customized for clinical radiopharmaceutical production. Our findings demonstrate that the Pb-203/Pb-212 combination is a promising elementally-matched radionuclide pair for image-guided radionuclide therapy for melanoma, neuroendocrine tumors, and potentially other cancers.
Collapse
Affiliation(s)
- Mengshi Li
- Interdisciplinary Graduate Program in Human Toxicology, University of Iowa, Iowa City, IA, USA.
| | - Xiuli Zhang
- Department of Biochemistry, University of Missouri, Columbia, MO USA
| | - Thomas P Quinn
- Department of Biochemistry, University of Missouri, Columbia, MO USA
| | - Dongyoul Lee
- Interdisciplinary Graduate Program in Human Toxicology, University of Iowa, Iowa City, IA, USA
| | - Dijie Liu
- Stead Family Department of Pediatrics, University of Iowa, Iowa City, IA, USA
| | - Falk Kunkel
- Eckert & Ziegler Radiopharma GmbH, Berlin, Germany
| | - Brian E Zimmerman
- National Institute of Standards and Technology, Gaithersburg, MD, USA
| | | | | | - Yusuf Menda
- Department of Radiology, The University of Iowa, Iowa City, IA, USA
| | - Saed Mirzadeh
- Oak Ridge National Laboratory, The US Department of Energy, Oak Ridge, TN, USA
| | - Roy Copping
- Oak Ridge National Laboratory, The US Department of Energy, Oak Ridge, TN, USA
| | - Frances L Johnson
- Viewpoint Molecular Targeting, LLC, Coralville, IA, USA; Department of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, IA, USA
| | - Michael K Schultz
- Interdisciplinary Graduate Program in Human Toxicology, University of Iowa, Iowa City, IA, USA; Stead Family Department of Pediatrics, University of Iowa, Iowa City, IA, USA; Department of Radiology, The University of Iowa, Iowa City, IA, USA; Viewpoint Molecular Targeting, LLC, Coralville, IA, USA; Department of Radiation Oncology (Free Radical and Radiation Biology Program), Carver College of Medicine, University of Iowa, Iowa City, IA, USA; Department of Chemistry, University of Iowa, Iowa City, IA, USA.
| |
Collapse
|
25
|
Miran T, Vogg ATJ, El Moussaoui L, Kaiser HJ, Drude N, von Felbert V, Mottaghy FM, Morgenroth A. Dual addressing of thymidine synthesis pathways for effective targeting of proliferating melanoma. Cancer Med 2017; 6:1639-1651. [PMID: 28608446 PMCID: PMC5504322 DOI: 10.1002/cam4.1113] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2017] [Revised: 04/21/2017] [Accepted: 05/02/2017] [Indexed: 12/21/2022] Open
Abstract
Here, we examined the potential of blocking the thymidine de novo synthesis pathways for sensitizing melanoma cells to the nucleoside salvage pathway targeting endogenous DNA irradiation. Expression of key nucleotide synthesis and proliferation enzymes thymidylate synthase (TS) and thymidine kinase 1 (TK1) was evaluated in differentiated (MITFhigh [microphthalmia‐associated transcription factor] IGR1) and invasive (MITFmediumIGR37) melanoma cells. For inhibition of de novo pathways cells were incubated either with an irreversible TS inhibitor 5‐fluoro‐2′‐deoxyuridine (FdUrd) or with a competitive dihydrofolate‐reductase (DHFR) inhibitor methotrexate (MTX). Salvage pathway was addressed by irradiation‐emitting thymidine analog [123/125I]‐5‐iodo‐4′‐thio‐2′‐deoxyuridine (123/125I‐ITdU). The in vivo targeting efficiency was visualized by single‐photon emission computed tomography. Pretreatment with FdUrd strongly increased the cellular uptake and the DNA incorporation of 125I‐ITdU into the mitotically active IGR37 cells. This effect was less pronounced in the differentiated IGR1 cells. In vivo, inhibition of TS led to a high and preferential accumulation of 123I‐ITdU in tumor tissue. This preclinical study presents profound rationale for development of therapeutic approach by highly efficient and selective radioactive targeting one of the crucial salvage pathways in melanomas.
Collapse
Affiliation(s)
- Tara Miran
- Department of Nuclear Medicine, University Hospital Aachen, RWTH Aachen University, 30 Pauwelsstrasse, Aachen, 52074, Germany
| | - Andreas T J Vogg
- Department of Nuclear Medicine, University Hospital Aachen, RWTH Aachen University, 30 Pauwelsstrasse, Aachen, 52074, Germany
| | - Laila El Moussaoui
- Department of Nuclear Medicine, University Hospital Aachen, RWTH Aachen University, 30 Pauwelsstrasse, Aachen, 52074, Germany
| | - Hans-Jürgen Kaiser
- Department of Nuclear Medicine, University Hospital Aachen, RWTH Aachen University, 30 Pauwelsstrasse, Aachen, 52074, Germany
| | - Natascha Drude
- Department of Nuclear Medicine, University Hospital Aachen, RWTH Aachen University, 30 Pauwelsstrasse, Aachen, 52074, Germany
| | - Verena von Felbert
- Department of Dermatology and Allergology, University Hospital RWTH Aachen, 30 Pauwelsstrasse, Aachen, 52074, Germany
| | - Felix M Mottaghy
- Department of Nuclear Medicine, University Hospital Aachen, RWTH Aachen University, 30 Pauwelsstrasse, Aachen, 52074, Germany.,Department of Nuclear Medicine, Maastricht University Medical Center, Maastricht, the Netherlands
| | - Agnieszka Morgenroth
- Department of Nuclear Medicine, University Hospital Aachen, RWTH Aachen University, 30 Pauwelsstrasse, Aachen, 52074, Germany
| |
Collapse
|
26
|
Abstract
OBJECTIVE This article reviews recent developments in targeted radionuclide therapy (TRT) approaches directed to malignant liver lesions, bone metastases, neuroendocrine tumors, and castrate-resistant metastatic prostate cancer and discusses challenges and opportunities in this field. CONCLUSION TRT has been employed since the first radioiodine thyroid treatment almost 75 years ago. Progress in the understanding of the complex underlying biology of cancer and advances in radiochemistry science, multimodal imaging techniques including the concept of "see and treat" within the framework of theranostics, and universal traction with the notion of precision medicine have all contributed to a resurgence of TRT.
Collapse
|
27
|
Rbah-Vidal L, Vidal A, Billaud EMF, Besse S, Ranchon-Cole I, Mishellany F, Perrot Y, Maigne L, Moins N, Guerquin-Kern JL, Degoul F, Chezal JM, Auzeloux P, Miot-Noirault E. Theranostic Approach for Metastatic Pigmented Melanoma Using ICF15002, a Multimodal Radiotracer for Both PET Imaging and Targeted Radionuclide Therapy. Neoplasia 2016; 19:17-27. [PMID: 27987437 PMCID: PMC5157796 DOI: 10.1016/j.neo.2016.11.001] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2016] [Accepted: 11/01/2016] [Indexed: 01/05/2023] Open
Abstract
PURPOSE: This work reports, in melanoma models, the theranostic potential of ICF15002 as a single fluorinated and iodinated melanin-targeting compound. METHODS: Studies were conducted in the murine syngeneic B16BL6 model and in the A375 and SK-MEL-3 human xenografts. ICF15002 was radiolabeled with fluorine-18 for positron emission tomography (PET) imaging and biodistribution, with iodine-125 for metabolism study, and iodine-131 for targeted radionuclide therapy (TRT). TRT efficacy was assessed by tumor volume measurement, with mechanistics and dosimetry parameters being determined in the B16BL6 model. Intracellular localization of ICF15002 was characterized by secondary ion mass spectrometry (SIMS). RESULTS: PET imaging with [18F]ICF15002 evidenced tumoral uptake of 14.33 ± 2.11%ID/g and 4.87 ± 0.93%ID/g in pigmented B16BL6 and SK-MEL-3 models, respectively, at 1 hour post inoculation. No accumulation was observed in the unpigmented A375 melanoma. SIMS demonstrated colocalization of ICF15002 signal with melanin polymers in melanosomes of the B16BL6 tumors. TRT with two doses of 20 MBq [131I]ICF15002 delivered an absorbed dose of 102.3 Gy to B16BL6 tumors, leading to a significant tumor growth inhibition [doubling time (DT) of 2.9 ± 0.5 days in treated vs 1.8 ± 0.3 in controls] and a prolonged median survival (27 days vs 21 in controls). P53S15 phosphorylation and P21 induction were associated with a G2/M blockage, suggesting mitotic catastrophe. In the human SK-MEL-3 model, three doses of 25 MBq led also to a DT increase (26.5 ± 7.8 days vs 11.0 ± 3.8 in controls) and improved median survival (111 days vs 74 in controls). CONCLUSION: Results demonstrate that ICF15002 fulfills suitable properties for bimodal imaging/TRT management of patients with pigmented melanoma.
Collapse
Affiliation(s)
- Latifa Rbah-Vidal
- UMR 990 INSERM/Université d'Auvergne, F-63005 Clermont-Ferrand, France; UMR 892 INSERM/6299 CNRS/Université de Nantes, F-44007 Nantes, France
| | - Aurélien Vidal
- UMR 990 INSERM/Université d'Auvergne, F-63005 Clermont-Ferrand, France; Arronax, CS 10112, F-44817 Saint Herblain Cedex, France
| | | | - Sophie Besse
- UMR 990 INSERM/Université d'Auvergne, F-63005 Clermont-Ferrand, France
| | - Isabelle Ranchon-Cole
- UMR 1107 INSERM/Université d'Auvergne, Equipe Biophysique Neurosensorielle, F-63000 Clermont-Ferrand, France
| | - Florence Mishellany
- Centre Jean Perrin, Laboratoire d'anatomo-pathologie, F-63011 Clermont-Ferrand, France
| | - Yann Perrot
- CNRS/IN2P3/Université Blaise Pascal, Laboratoire de Physique Corpusculaire, F-63000 Clermont-Ferrand, France
| | - Lydia Maigne
- CNRS/IN2P3/Université Blaise Pascal, Laboratoire de Physique Corpusculaire, F-63000 Clermont-Ferrand, France
| | - Nicole Moins
- UMR 990 INSERM/Université d'Auvergne, F-63005 Clermont-Ferrand, France
| | | | - Françoise Degoul
- UMR 990 INSERM/Université d'Auvergne, F-63005 Clermont-Ferrand, France
| | | | - Philippe Auzeloux
- UMR 990 INSERM/Université d'Auvergne, F-63005 Clermont-Ferrand, France
| | | |
Collapse
|
28
|
Moadel RM. Letter from the Guest Editor: Arsenal Continued. Semin Nucl Med 2016; 46:182-3. [PMID: 27067499 DOI: 10.1053/j.semnuclmed.2016.02.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|